The three doses of ZyCoV-D are to be administered 28 days apart. The vaccine was given emergency use authorisation (EUA) by the Indian drug regulator on August 20
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
Filing marks first protein-based vaccine submitted to MHRA for authorization
The revised deal involves a cash consideration only as against the earlier proposal of cash and equity
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
CuraTeQ Biologics is on track for filing a second oncology biosimilar
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
Cephalosporin is a bactericidal, broad-spectrum, and P-lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis among others
The company said in a regulatory filing that it was confident of addressing the observations satisfactorily
Subscribe To Our Newsletter & Stay Updated
